BESREMi is a preferred, FDA-approved option for both symptomatic low- and high-risk polycythemia vera patients. In the polycythemia vera space, BESRE ...
The "Myelofibrosis (MF) - Market Insight, Epidemiology, and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. The report delivers an in-depth understanding of the ...
Bristol Myers Squibb today announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque ...
Aclaris Therapeutics (ACRS) announced the availability of a new publication describing properties of Aclaris Therapeutics’ ATI-2138, a novel ...
Data Generated to Date Support Potential for Aclaris’ ATI-2138 to Impact Several Human Inflammatory Diseases - WAYNE, Pa., ...
The Board of Directors of Aqilion AB (publ) ("Aqilion" or the "Company") has on 11 February 2025, based on the authorization granted by the Annual General Meeting on 10 June 2024, resolved to carry ...
Pharmaceutical ads are difficult to avoid in American television programming and a growing number of them promote a class of ...
Researchers have used AI to find adalimumab effective for iMCD, highlighting the potential of machine learning in discovering ...
Moving forward, Fajgenbaum and his team are gearing up to launch a clinical trial this year of the effectiveness of another repurposed drug, this one a JAK1/2 inhibitor, on iMCD. This study was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback